BioCentury | Jul 6, 2018
Company News

Management tracks: Goldman Sachs, Acceleron

...Lehner as scientific SVP. He was CMO of Sanofi (Euronext:SAN; NYSE:SNY). Regenerative medical device company Tissue Regenix Group plc...
BioCentury | Nov 3, 2017
Company News

Management tracks: Tissue Regenix, Therapix

...Regenerative medical device company Tissue Regenix Group plc (LSE:TRX) named Steve Couldwell CEO. A Tissue Regenix director since 2013, Couldwell...
BioCentury | Oct 18, 2017
Company News

Management tracks: Gilead, Ipsen, Depomed

...of Arup Laboratories (Salt Lake City, Utah). Boston Biomedical develops cancer therapeutics. Regenerative medicine company Tissue Regenix Group plc...
BioCentury | Feb 9, 2015
Financial News

Tissue Regenix completes placing

Tissue Regenix Group plc (LSE:TRX), York, U.K. Business: Gene/Cell therapy, Transplant Date completed: 2015-01-22 Type: Placing Raised: £20 million ($30.3 million) Shares: 105.3 million Price: 19p Shares after offering: 759.4 million Investor: Institutional investors Underwriter:...
BioCentury | Jun 23, 2014
Company News

Tissue Regenix Group pl sales and marketing update

...Tissue Regenix launched DermaPure in the U.S. to treat chronic wounds. Tissue Regenix also said it signed...
...not rejected by the patient’s body. Tissue Regenix declined to disclose pricing for a DermaPure treatment. Tissue Regenix...
BioCentury | Feb 18, 2013
Clinical News

Tissue Regenix preclinical data

...was safe with no systemic adverse effects or inflammatory responses related to the device reported. Tissue Regenix...
...European pivotal trial of the non-cellular porcine meniscus repair implant made using decellularization (dCELL) technology. Tissue Regenix Group plc...
BioCentury | Oct 15, 2012
Clinical News

DCELL Dermis: Interim Pilot trial data

...to conventional treatments. dCELL Dermis is used in conjunction with a portable compression therapy system. Tissue Regenix Group plc...
BioCentury | Jun 4, 2012
Company News

Tissue Regenix, NHS Blood and Transplant deal

...Blood and Transport (NHSBT) in order to expand the scope of clinical development activities for Tissue Regenix's...
...the NHS. The expansion includes the development of decellularized human dermis and products for cardiology. Tissue Regenix...
...company to fast track the clinical evaluation of additional human tissue applications for the technology. Tissue Regenix...
BioCentury | Dec 12, 2011
Finance

Highlights of weekly biotech stock moves

...General to review the contract. Siga was up $0.37 (18%) on the week. Transplant company Tissue Regenix Group plc...
BioCentury | Dec 12, 2011
Financial News

Tissue Regenix proposes placing

Tissue Regenix Group plc (LSE:TRX), York, U.K. Business: Gene/Cell therapy, Transplant Date announced: 12/8/11 Type: Placing To be raised: £25 million ($39.1 million) Shares: 181.8 million Price: 13.75p Underwriter: Peel Hunt Shares outstanding prior: 470.6...
Items per page:
1 - 10 of 16
BioCentury | Jul 6, 2018
Company News

Management tracks: Goldman Sachs, Acceleron

...Lehner as scientific SVP. He was CMO of Sanofi (Euronext:SAN; NYSE:SNY). Regenerative medical device company Tissue Regenix Group plc...
BioCentury | Nov 3, 2017
Company News

Management tracks: Tissue Regenix, Therapix

...Regenerative medical device company Tissue Regenix Group plc (LSE:TRX) named Steve Couldwell CEO. A Tissue Regenix director since 2013, Couldwell...
BioCentury | Oct 18, 2017
Company News

Management tracks: Gilead, Ipsen, Depomed

...of Arup Laboratories (Salt Lake City, Utah). Boston Biomedical develops cancer therapeutics. Regenerative medicine company Tissue Regenix Group plc...
BioCentury | Feb 9, 2015
Financial News

Tissue Regenix completes placing

Tissue Regenix Group plc (LSE:TRX), York, U.K. Business: Gene/Cell therapy, Transplant Date completed: 2015-01-22 Type: Placing Raised: £20 million ($30.3 million) Shares: 105.3 million Price: 19p Shares after offering: 759.4 million Investor: Institutional investors Underwriter:...
BioCentury | Jun 23, 2014
Company News

Tissue Regenix Group pl sales and marketing update

...Tissue Regenix launched DermaPure in the U.S. to treat chronic wounds. Tissue Regenix also said it signed...
...not rejected by the patient’s body. Tissue Regenix declined to disclose pricing for a DermaPure treatment. Tissue Regenix...
BioCentury | Feb 18, 2013
Clinical News

Tissue Regenix preclinical data

...was safe with no systemic adverse effects or inflammatory responses related to the device reported. Tissue Regenix...
...European pivotal trial of the non-cellular porcine meniscus repair implant made using decellularization (dCELL) technology. Tissue Regenix Group plc...
BioCentury | Oct 15, 2012
Clinical News

DCELL Dermis: Interim Pilot trial data

...to conventional treatments. dCELL Dermis is used in conjunction with a portable compression therapy system. Tissue Regenix Group plc...
BioCentury | Jun 4, 2012
Company News

Tissue Regenix, NHS Blood and Transplant deal

...Blood and Transport (NHSBT) in order to expand the scope of clinical development activities for Tissue Regenix's...
...the NHS. The expansion includes the development of decellularized human dermis and products for cardiology. Tissue Regenix...
...company to fast track the clinical evaluation of additional human tissue applications for the technology. Tissue Regenix...
BioCentury | Dec 12, 2011
Finance

Highlights of weekly biotech stock moves

...General to review the contract. Siga was up $0.37 (18%) on the week. Transplant company Tissue Regenix Group plc...
BioCentury | Dec 12, 2011
Financial News

Tissue Regenix proposes placing

Tissue Regenix Group plc (LSE:TRX), York, U.K. Business: Gene/Cell therapy, Transplant Date announced: 12/8/11 Type: Placing To be raised: £25 million ($39.1 million) Shares: 181.8 million Price: 13.75p Underwriter: Peel Hunt Shares outstanding prior: 470.6...
Items per page:
1 - 10 of 16